Author + information
- Takashi Matsumoto,
- Wen–Loong Yeow,
- Asma Hussaini,
- Mane Arabyan,
- Amin Manuchehry,
- Mamoo Nakamura,
- Moody Makar,
- Swaminatha Gurudevan,
- Takahiro Shiota,
- Alfredo Trento and
- Saibal Kar
MitraClip (Abbott Vascular, Menlo Park, California) is an effective low risk transcatheter treatment option for the treatment of functional mitral regurgitation (FMR). Pulmonary hypertension (PH) is a predictor of adverse outcome following mitral valve surgery. However, the prognostic implications of preoperative PH on FMR patients undergoing MitraClip procedure remain uncertain.
Eighty–six FMR patients undergoing MitraClip procedure were divided into 2 groups; non–PH (n = 39) and PH group (n = 47). PH was defined as systolic pulmonary artery pressure (sPAP) greater than 50 mm Hg using Doppler transthoracic echocardiography.
The baseline sPAP in PH and non–PH groups were 64 ± 9 and 39 ± 10 mm Hg, respectively. Mean follow up was 520 ± 416 days. Acute procedural success was similar in both PH and non–PH groups (91.5% vs. 97.4%, p = NS). At 1–year follow up, sPAP significantly decreased in PH group (from 63 ± 8 mm Hg to 53 ± 15 mm Hg; p = 0.006), but not in non–PH group (from 38 ± 12 mm Hg to 37 ± 12 mm Hg; p = NS). The cumulative survival rate by Kaplan–Meier analysis (Figure 1) was 87.2% vs. 86.4% at 1–year, 53.3% vs. 82.6% at 2–year in PH and non–PH group, respectively (log–rank p = 0.005). In multivariable analyses, preoperative PH was associated with increased all–cause death (hazard ratio, 3.79; 95% confidence interval, 1.35–10.62; p = 0.011).
Preoperative PH is a significant predictor of long–term survival after the MitraClip procedure for FMR.
Moderated Poster Contributions
Poster Sessions, Expo North
Monday, March 11, 2013, 9:45 a.m.–10:30 a.m.
Session Title: Structural Heart Disease Intervention
Abstract Category: 50. TCT@ACC–i2: Mitral Valve Disease
Presentation Number: 2114M–248
- 2013 American College of Cardiology Foundation